Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

By L. Jacobsson, C. Turesson, A. Gülfe, M. Kapetanovic, I. Petersson, T. Saxne, P. Geborek. Journal of Rheumatology, 2005

598 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. (2006, background): “†Not reported in original publication; on file with US Food and Drug Administration (http://www.fda.gov/_Hlt94332169o_Hlt94332169hrms/dockets/ac/03/briefing /3930B1_01_C--_Hlt103512168_Hlt103512168HUMIRA.Med.Review.pdf).”
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register (2007, background): “Low numbers of events (n 13) and a short followup time (656 personyears) in the anti-TNF cohort in that study precluded further analysis (18).”